Stockreport

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 

Lyell Immunopharma, Inc.  (LYEL) 
PDF Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control r [Read more]